Skip to content
    Clinical Trials

    Short-Course RT With Camrelizumab Improves 3-Year Event-Free Survival in Rectal Cancer

    Tao et alThe Lancet Oncology

    Short-Course RT With Camrelizumab Improves 3-Year Event-Free Survival in Rectal Cancer
    In a prespecified interim analysis of the multicenter, open-label, randomized, phase 3 UNION trial, neoadjuvant short-course radiotherapy followed by camrelizumab and CAPOX was evaluated against standard of care in patients with locally advanced rectal cancer.
    The regimen of short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival compared with standard long-course chemoradiotherapy followed by CAPOX. In the intention-to-treat population, the 3-year investigator-assessed event-free survival rate was 91.3% (95% CI 83.9–95.4) with short-course radiotherapy followed by camrelizumab and CAPOX versus 77.4% (95% CI 67.9–84.4) with standard of care (stratified hazard ratio 0.33, 95% CI 0.15–0.71; two-sided log-rank p = 0.0029). In addition, the experimental regimen showed a safety profile similar to the standard-of-care comparator.
    The study authors note that comparison of this treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.

    Key Takeaways

    • Neoadjuvant short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival compared with standard long-course chemoradiotherapy followed by CAPOX in patients with locally advanced rectal cancer (3-year event-free survival 91.3% vs 77.4%; stratified HR 0.33, 95% CI 0.15–0.71).
    • The regimen of short-course radiotherapy followed by camrelizumab and CAPOX showed a safety profile similar to long-course chemoradiotherapy followed by CAPOX.
    Read the original sourceThe Lancet Oncology